Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study - PubMed
3 hours ago
- #Follicular Lymphoma
- #Lenalidomide
- #Phase II Trial
- The study evaluated lenalidomide-rituximab (R2) versus R2 plus bendamustine (R2B) for relapsed/refractory follicular lymphoma in a randomized phase II trial.
- Complete remission rates at end-of-induction were low: 11.4% for R2 and 15.2% for R2B, with severe toxicity rates of 6.8% and 13.0%, respectively.
- At 60 months, event-free survival was 39.5% for R2 and 56.4% for R2B, and overall survival was 72.1% versus 86.3%, with R2B showing longer survival but higher toxicity.